TKG Advisors’s AbbVie ABBV Stock Holding History

TKG Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.19M	Buy	12,662 +746	+6%	+$160K	1.11%	27
2026 Q1	$2.59M	Sell	11,916 -5	-0%	-$1.11K	1.07%	36
2025 Q4	$2.72M	Sell	11,921 -713	-6%	-$162K	1.1%	32
2025 Q3	$2.93M	Buy	12,634 +261	+2%	+$53.1K	1.25%	26
2025 Q2	$2.3M	Buy	12,373 +561	+5%	+$104K	1.03%	33
2025 Q1	$2.47M	Sell	11,812 -1,747	-13%	-$340K	1.22%	28
2024 Q4	$2.31M	Buy	+13,559	New	+$2.49M	1.06%	32
2024 Q1	–	Sell	-1,592	Closed	-$247K	–	94
2023 Q4	$247K	Sell	1,592 -4	-0.3%	-$583	0.15%	87
2023 Q3	$238K	Buy	+1,596	New	+$234K	0.16%	87
2023 Q2	–	Sell	-4,202	Closed	-$670K	–	97
2023 Q1	$670K	Buy	+4,202	New	+$642K	0.42%	49

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TKG Advisors's ABBV Position: Q2 2026 in Review

TKG Advisors increased its AbbVie (ABBV) stake by 6.3% in Q2 2026, buying an estimated $160K and bringing the position to 12,662 shares worth $3.19M. The position accounts for 1.11% of the portfolio, ranked #27.

TKG Advisors first reported a position in ABBV in Q1 2023 and has held it in 10 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

TKG Advisors held 12,662 shares of AbbVie worth $3.19M as of Q2 2026.
TKG Advisors bought 746 AbbVie shares in Q2 2026, an estimated $160K.
AbbVie made up 1.11% of TKG Advisors's portfolio in Q2 2026, its #27 holding.
TKG Advisors first reported a position in AbbVie in Q1 2023 and has held it in 10 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on TKG Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.